4.3. Stone-specific metabolic evaluation and pharmacological recurrence prevention. 4.3.1. Introduction Pharmacological treatment is necessary in patients at high risk for stone formation or for associated systemic conditions. The ideal drug should halt stone formation, have no side effects, and be easy to administer. Each of these aspects is important to achieve good compliance. Table 4.6 highlights the most important characteristics of commonly used medication. Table 4.6: Pharmacological substances used for stone prevention - characteristics, specifics, and dosage. AgentRationaleDoseSpecifics and side effectsStone typeRefAlkaline citratesAlkalinisationHypocitraturiaInhibition ofcalcium oxalatecrystallisation3.25-9.75 g/d(10-30 mmol/d)Children:0.1-0.15 g/kg/dDaily dose foralkalinisation dependson urine pH.Calcium oxalateUric acidCystine[587-592]AllopurinolHyperuricosuriaHyperuricaemia100-300 mg/dChildren:1-3 mg/kg/d100 mg in isolatedhyperuricosuria.Renal insufficiencydemands dosecorrection.Contraindicated in acute gout pregnancy, and breastfeeding.Allergies from trivial to very severe forms, xanthine stone formation.Calcium oxalateUric acidAmmonium urate2,8-Dihydroxyadenine[557,593-596]CalciumEnterichyperoxaluriaUp to 2,000mg/d dependingon oxalateexcretionIntake 30 min before meals.Calcium oxalate[577,579,580,597]CaptoprilCystinuriaActive decrease of urinary cystine levels75-150 mgSecond-line option in case of significant side effects of tiopronin.Cystine[598,599]FebuxostatHyperuricosuriaHyperuricaemia80-120 mg/dContraindicated in acute gout, pregnancy and breastfeeding.Xanthine stone formation.Calcium oxalateUric acid[600,601]L-MethionineAcidification600-1,500 mg/dHypercalciuria, bonedemineralisation,systemic acidosis.No long-term therapy.Infection stonesAmmonium urateCalcium phosphate[587,602]MagnesiumIsolatedHypomagnesuriaEnterichyperoxaluria200-400 mg/dChildren:6 mg/kg/dRenal insufficiencydemands dosecorrection.Diarrhoea, chronic alkali losses,hypocitraturia.Calcium oxalate[603,604](Low levelofevidence)Sodium bicarbonateAlkalinisationHypocitraturia4.5 g/dDaily dose foralkalinisation dependson urine pHCalcium oxalateUric acid, Cystine[605]PyridoxinePrimaryhyperoxaluriaInitial dose5 mg/kg/dMax. 20 mg/kg/dSensory peripheral neuropathyCalcium oxalate[606]Thiazide(Hydro-chlorothiazide*)Hypercalciuria25-50 mg/dChildren:0.5-1 mg/kg/dRisk for hypotensiondiabetes,hyperuricaemia,hypokalaemia,hypocitraturia.Calcium oxalateCalcium phosphate[583,587-596,598-616]TioproninCystinuriaIncrease in solubility of levelsInitial dose800 mg/dAvg. 2,000 mg/d**Children:Initial dose in patients > 20kg is 15 mg/kg/day.Avoid dosages > 50mg/kg/dayRisk forproteinuria.Cystine[617-620] * Patients on hydrochlorothiazide should be advised to get their skin checked on a regular basis as they have a higher risk of developing a non-melanoma skin cancer (NMSC) and some forms of melanoma. In patients with a history of skin cancer, the indication for treatment with hydrochlorothiazide should be thoroughly reviewed [621-623]** No information is available on maximum dose and patients may be initiated on a very low dose if they have previously had reactions to tiopronin or penicillamine. For all patients, dosage should be titrated according to the frequency of stone episodes, side effects, and renal function under expert supervision with close monitoring. 